Qure.ai’s Post

#ArtificialIntelligence is a powerful advancement in the #earlydetection of #lungcancer. In a multi-reader, multi-case clinical validation study, Qure.ai's FDA-cleared qXR-LN enhanced pulmonary nodule detection performance for radiologists, pulmonologists, and ER physicians, #transformingdiagnostics. By providing a 'second pair of eyes' to review plain film X-rays, #medicalimaging AI can help expedite referral to CT investigations and subsequent treatment planning. This supports the fight against lung cancer. Find out more here - https://lnkd.in/d9B_yPvt Samir Shah, MD, MMM FACR Ankit Modi Rohit Ghosh Anumeha Srivastava Divya Gupta Dr. Charu Arora Nate Hunter Chris Pordon Dhruv Pandey Anish Chhaparwal Daniel Lehewych Georgina Wright Rakhee Krishnan Bhargava Reddy

Avenda Health and EDAP TMS, a leader in robotic therapies, have announced a partnership to introduce Unfold AI®-Assisted Focal One technology for prostate cancer treatment. Earlier this month, the @UCLA School of Medicine successfully conducted the first procedures using this new technology. This FDA-cleared AI platform enables urologists to provide personalized robotic high-intensity focused ultrasound (HIFU) ablation tailored to individual patients. Dr. Wayne G. Brisbane from UCLA highlighted the enhanced precision by integrating AI with the Focal One platform, which minimizes side effects during treatment. Avenda CEO Shyam Natarajan expressed excitement about the collaboration, emphasizing the potential of their AI technology to improve cancer treatment outcomes. Ryan Rhodes, CEO of EDAP TMS, also praised the partnership, noting that combining Unfold AI with Focal One’s software significantly enhances surgical planning and execution. Click the link below to read the full article. #ArtificialIntelligence #ProstateCancer #AvendaHealth #ProudInvestor #WealthingVCClub

Qure.ai’s AI-powered chest X-ray interpretation tool, #qXR, is central to the Radiograph Accelerated Detection and Identification of Cancer in the Lung (RADICAL) study, a pioneering research effort led by NHS Greater Glasgow and Clyde and Prof David Lowe. This study aims to evaluate the effectiveness of #AI in the early detection of #lungcancer, the leading cause of cancer-related deaths in the #UK. With #radiology departments under immense strain due to a shortage of #radiologists and growing backlogs, the study investigates whether AI can reduce diagnostic delays. By integrating Qure.ai’s qXR solution into routine clinical workflows, researchers hope to demonstrate how AI can prioritize urgent suspicious #cancer cases, expedite #diagnoses, and enhance efficiency. The goal is to showcase AI’s potential in reducing time-to-diagnosis for lung cancer and improving patient outcomes in high-demand #healthcare settings. Read more about the study findings here: https://lnkd.in/ezmyfEg7

Excited to share that Qure.ai’s AI-powered chest X-ray tool, qXR, is at the heart of the RADICAL study led by NHS Greater Glasgow and Clyde and Prof David Lowe. This research studied AI’s role in early lung cancer detection, the leading cause of cancer deaths in the UK. With radiology departments facing immense pressure from a shortage of radiologists and increasing backlogs, this study explores how AI can help reduce diagnostic delays. By integrating qXR into routine workflows, we aim to show how AI can prioritise urgent suspicious cancers, speed up diagnoses, and improve efficiency. Our goal is to demonstrate AI’s potential in reducing time to diagnosis for lung cancer and enhancing patient outcomes in high-demand healthcare settings. Read more about the study here: https://lnkd.in/gXkUWDvp Digital Health Validation Lab NHS Greater Glasgow and Clyde Mark Hall Sean Duncan David Lowe Samir Shah, MD, MMM FACR Preetham Putha Ranjana Devi Aman Garg Sagar Sen Georgina Wright Shamie Kumar Nate Hunter Pradeep Kumar Saniya Pawar #AI #lungcancer #UK #radiology #NHS

AI is doing the groundwork to bring more clarity to breast cancer screenings. Read the story: A clearer picture on Unlocked: https://lnkd.in/ganQmcgU

Inspired by how #AI is doing the groundwork to bring more clarity to breast cancer screenings. Read the story: A clearer picture on Unlocked: https://lnkd.in/ganQmcgU #MSFTAdvocate #MicrosoftAI

"With instances of breast cancer in younger women on the rise and existing disparities in breast cancer mortality rates holding strong, particularly among Black women who are about 40% more likely to die from the disease than White women, clear and actionable information for patients is critical." #AI is doing the groundwork to bring more clarity to breast cancer screenings. Read the story: A clearer picture on Unlocked: https://lnkd.in/ganQmcgU #MSFTAdvocate #MicrosoftAI

ai brings more clarity to breast cancer screenings

Prayers and Praise to help get ahead of a disease that impacts so many!! #AI is doing the groundwork to bring more clarity to breast cancer screenings. Read the story: A clearer picture on Unlocked: https://lnkd.in/ganQmcgU #MSFTAdvocate #MicrosoftAI

🔍 Discover CINA-iPE: Revolutionizing Opportunistic Pulmonary Embolism Detection for Oncology Patients 🩺 Introducing CINA-iPE, our cutting-edge product designed to detect incidental pulmonary embolism (PE) in oncology patients undergoing imaging for reasons other than suspicion of PE. Oncology patients often present with atypical symptoms, making PE diagnosis challenging. With CINA-iPE, we've developed a solution that addresses these challenges head-on, empowering clinicians to enhance patient care and outcomes. 🫁 Technical Points of CINA-iPE: Pulmonay Embolism Diagnosed Incidentally: CINA-iPE detects PE incidentally during imaging for reasons other than suspicion of PE. CT Scan Type for Detection: Effective in Staging scans and Thoracic-Abdominal-Pelvic (TAP) scans. 🚀 What sets CINA-iPE apart? Advanced AI Technology: Powered by state-of-the-art artificial intelligence, CINA-iPE ensures unparalleled accuracy in detecting PE, even in its subtlest forms. Focus on Oncology Patients: Tailored specifically to cater to the needs of oncology patients, ensuring early detection and timely intervention, ultimately saving lives. Seamless Integration: CINA-iPE seamlessly integrates into existing radiology workflows, enhancing efficiency without disrupting established practices. Ready to learn more? Book a demo online to discover how CINA-iPE can transform pulmonary embolism detection in your practice: https://lnkd.in/ezKz92cJ Don't miss this chance to lead the way in radiology and oncology care innovation. #AvicennaAI #CINAiPE #PulmonaryEmbolism #Oncology #Radiology #Innovation #PatientCare